Dexpramipexole

Dexpramipexole

SCHEMBL2289178

CCCN[C@@H]1CCc2nc(N)sc2C1.Cl.Cl.O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DRD2DRD3DRD4

The experimentally established mechanism targets of Dexpramipexole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 known ✓ P35462 5/20 1.00
DRD2 known ✓ P14416 5/20 1.00
DRD4 known ✓ P21917 2/20 1.00
ADRA2A P08913 2/20 0.97
HRH2 P25021 2/20 0.95
ADRB2 P07550 1/20 0.95
HTR1A P08908 1/20 0.95
ADRA2B P18089 1/20 0.95
ADRA2C P18825 1/20 0.95
HTR1B P28222 1/20 0.95
HTR2A P28223 1/20 0.95
HTR7 P34969 1/20 0.95
ADRA1A P35348 1/20 0.95
HRH1 P35367 1/20 0.95
HTR2B P41595 1/20 0.95
SIGMAR1 Q99720 1/20 0.95
HRH4 Q9H3N8 1/20 0.95
SCN3A Q9NY46 5/20 0.54
SCN4A P35499 4/20 0.54
SCN9A Q15858 4/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pramipexole SCHEMBL22165339 1.00 DRD3 (1.00) DRD3DRD2DRD4ADRA2AHRH2
Pramipexole SCHEMBL28361114 1.00 DRD3 (1.00) DRD3DRD2DRD4ADRA2AHRH2
Pramipexole SCHEMBL3947282 1.00 DRD3 (1.00) DRD3DRD2DRD4ADRA2AHRH2
Pramipexole SCHEMBL28345162 1.00 DRD3 (1.00) DRD3DRD2DRD4ADRA2AHRH2
Pramipexole SCHEMBL2048695 1.00 DRD3 (1.00) DRD3DRD2DRD4ADRA2AHRH2
Pramipexole SCHEMBL153875 1.00 DRD3 (1.00) DRD3DRD2DRD4ADRA2AHRH2
Pramipexole SCHEMBL743891 1.00 DRD3 (1.00) DRD3DRD2DRD4ADRA2AHRH2
Pramipexole SCHEMBL28506481 1.00 DRD3 (1.00) DRD3DRD2DRD4ADRA2AHRH2
Dexpramipexole SCHEMBL910147 0.99 ADRA2A (1.00) DRD3DRD2DRD4ADRA2AHRH2
Pramipexole SCHEMBL20524815 0.99 DRD3 (0.97) DRD3DRD2DRD4ADRA2AHRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3838271-B1 TREATING ELEVATED LEVELS OF EOSINOPHILS AND/OR BASOPHILS ARETEIA THERAPEUTICS INC (US) 2025-09-03 EP claimed
US-20250213489-A1 OSMOTIC TABLETS OF DEXPRAMIPEXOLE AND METHODS OF MANUFACTURING AND USE THEREOF ARETEIA THERAPEUTICS, INC. (US) 2025-07-03 US claimed
EP-4578509-A2 TREATING ELEVATED LEVELS OF EOSINOPHILS AND/OR BASOPHILS Areteia Therapeutics, Inc. (US) 2025-07-02 EP claimed
WO-2025137498-A1 MATRIX TABLETS OF DEXPRAMIPEXOLE AND METHODS OF MANUFACTURING AND USE THEREOF ARETEIA THERAPEUTICS, INC. (US) 2025-06-26 WO claimed
WO-2025137502-A1 OSMOTIC TABLETS OF DEXPRAMIPEXOLE AND METHODS OF MANUFACTURING AND USE THEREOF ARETEIA THERAPEUTICS, INC. (US) 2025-06-26 WO claimed
US-20250205207-A1 MATRIX TABLETS OF DEXPRAMIPEXOLE AND METHODS OF MANUFACTURING AND USE THEREOF ARETEIA THERAPEUTICS, INC. (US) 2025-06-26 US claimed
EP-4558622-A1 METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS Trailhead Biosystems Inc. (US) 2025-05-28 EP claimed
WO-2025088514-A1 METTL3-METTL14-COMPLEX INHIBITORS FOR THE TREATMENT OF NEUROMUSCULAR DEGENERATIVE PATHOLOGIES CAUSED BY OR LINKED TO MUTATIONS IN THE FUS GENE Università degli Studi di Roma “La Sapienza” (IT) 2025-05-01 WO claimed
US-20240368293-A1 Methods of Improving Recovery After Lung Resection UNIVERSITY OF MARYLAND, BALTIMORE (US) 2024-11-07 US claimed
US-20240117303-A1 METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS TRAILHEAD BIOSYSTEMS INC. 2024-04-11 US claimed
US-11026928-B2 Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils KNOPP BIOSCIENCES LLC (US) 2021-06-08 US claimed
EP-3019167-B1 TREATING ELEVATED LEVELS OF EOSINOPHILS AND/OR BASOPHILS KNOPP BIOSCIENCES LLC (US) 2021-02-17 EP claimed
US-10828284-B2 Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils KNOPP BIOSCIENCES LLC (US) 2020-11-10 US claimed
US-10383857-B2 Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils KNOPP BIOSCIENCES LLC (US) 2019-08-20 US claimed
US-20180271839-A1 COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO ELEVATED LEVELS OF EOSINOPHILS AND/OR BASOPHILS ARETEIA THERAPEUTICS, INC. 2018-09-27 US claimed
US-20180110758-A1 COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE KNOPP BIOSCIENCES LLC 2018-04-26 US claimed
US-9849116-B2 Compositions and methods of using (R)-pramipexole KNOPP BIOSCIENCES LLC (US) 2017-12-26 US claimed
US-20160158205-A1 COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO ELEVATED LEVELS OF EOSINOPHILS AND/OR BASOPHILS ARETEIA THERAPEUTICS, INC. 2016-06-09 US claimed
US-20160030397-A1 COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE ARETEIA THERAPEUTICS, INC. 2016-02-04 US claimed
US-20110190356-A1 Compositions and Methods of Using (R)- Pramipexole KNOPP NEUROSCIENCES INC. (US) 2011-08-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11026928-B2 Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils EPX, CMA1, CPA3 DRD3 1954/4885DRD2 2140/4885DRD4 1893/4885
US-20160030397-A1 COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE HSPE1, GRIN2B, GRIN2A DRD3 2160/4885DRD2 1622/4885DRD4 2604/4885
US-10383857-B2 Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils EPX, CMA1, CPA3 DRD3 1954/4885DRD2 2140/4885DRD4 1893/4885
US-10828284-B2 Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils EPX, CMA1, CPA3 DRD3 1954/4885DRD2 2140/4885DRD4 1893/4885
US-20180271839-A1 COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO ELEVATED LEVELS OF EOSINOPHILS AND/OR BASOPHILS EPX, CMA1, CPA3 DRD3 1954/4885DRD2 2140/4885DRD4 1893/4885
US-20160158205-A1 COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO ELEVATED LEVELS OF EOSINOPHILS AND/OR BASOPHILS EPX, CMA1, CPA3 DRD3 1954/4885DRD2 2140/4885DRD4 1893/4885
US-20250205207-A1 MATRIX TABLETS OF DEXPRAMIPEXOLE AND METHODS OF MANUFACTURING AND USE THEREOF EPX, CMA1, CPA3 DRD3 1370/4885DRD2 919/4885DRD4 839/4885
US-20250213489-A1 OSMOTIC TABLETS OF DEXPRAMIPEXOLE AND METHODS OF MANUFACTURING AND USE THEREOF EPX, CMA1, TSLP DRD3 990/4885DRD2 716/4885DRD4 629/4885
US-20180110758-A1 COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE HSPE1, GRIN2B, GRIN2A DRD3 2160/4885DRD2 1622/4885DRD4 2604/4885
US-20110190356-A1 Compositions and Methods of Using (R)- Pramipexole HSPE1, GRIN2B, GRIN2A DRD3 2284/4885DRD2 1704/4885DRD4 2734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.